Breast Cancer during Pregnancy as a Special Type of Early-Onset Breast Cancer: Analysis of the Tumor Immune Microenvironment and Risk Profiles.

PD-L1 biomarkers breast cancer breast cancer during pregnancy early-onset breast cancer pregnancy-related breast cancer tumor microenvironment tumor-infiltrating lymphocytes

Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
24 07 2022
Historique:
received: 15 05 2022
revised: 17 07 2022
accepted: 21 07 2022
entrez: 27 7 2022
pubmed: 28 7 2022
medline: 29 7 2022
Statut: epublish

Résumé

Breast cancer during pregnancy (PrBC) is a rare tumor with only a little information on its immune landscape. Here, we sought to characterize the cellular composition of the tumor microenvironment (TME) of PrBC and identify its differences from early-onset breast cancer (EOBC) in non-pregnant women. A total of 83 PrBC and 89 EOBC were selected from our Institutional registry and subjected to tumor-infiltrating lymphocytes (TILs) profiling and immunohistochemistry for CD4, CD8, forkhead box P3 (FOXP3), and programmed death-ligand 1 (PD-L1) (clone 22C3). A significantly lower frequency of hormone receptor (HR)-positive tumors was observed in PrBC. The prevalence of low/null PD-L1 and CD8+TILs was higher in PrBC than in the controls, specifically in HR+/HER2- breast cancers. PrBC had a significantly higher risk of relapse and disease-related death, compared to EOBC. The presence of TILs and each TIL subpopulation were significantly associated with disease relapse. Moreover, the death rate was higher in PrBC with CD8+ TILs. The TME of PrBC is characterized by specific patterns of TIL subpopulations with significant biological and prognostic roles. Routine assessment of TILs and TILs subtyping in these patients would be a valid addition to the pathology report that might help identify clinically relevant subsets of women with PrBC.

Identifiants

pubmed: 35892583
pii: cells11152286
doi: 10.3390/cells11152286
pmc: PMC9332147
pii:
doi:

Substances chimiques

B7-H1 Antigen 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Breast J. 2020 Apr;26(4):668-671
pubmed: 31448522
Lancet Oncol. 2021 Jun;22(6):753-754
pubmed: 34087122
Eur J Obstet Gynecol Reprod Biol. 2018 Nov;230:222-227
pubmed: 29728277
JCI Insight. 2020 Sep 17;5(18):
pubmed: 32809975
Endocr Relat Cancer. 2014 Aug;21(4):545-54
pubmed: 24825746
Obstet Gynecol. 2020 Jun;135(6):1457-1478
pubmed: 32459439
Front Immunol. 2014 May 08;5:196
pubmed: 24847324
Ann Oncol. 2015 Feb;26(2):259-71
pubmed: 25214542
Hum Reprod. 2019 Jan 01;34(1):25-36
pubmed: 30500923
Front Oncol. 2020 Sep 11;10:1773
pubmed: 33014874
Gynecol Oncol. 2020 Jun;157(3):799-809
pubmed: 32268951
J Immunol. 2012 Jul 15;189(2):1072-80
pubmed: 22685312
Clin Breast Cancer. 2021 Feb;21(1):e63-e73
pubmed: 32893093
Ann Oncol. 2013 Oct;24 Suppl 6:vi160-70
pubmed: 23813932
Am J Reprod Immunol. 2016 Jul;76(1):3-7
pubmed: 27293114
J Clin Invest. 2018 Oct 1;128(10):4224-4235
pubmed: 30272581
Eur J Immunol. 2020 Feb;50(2):160-169
pubmed: 31953958
Cancer Res. 2015 Jun 1;75(11):2139-45
pubmed: 25977340
Int J Cancer. 2018 Apr 1;142(7):1343-1354
pubmed: 29168177
Front Immunol. 2020 Oct 07;11:575197
pubmed: 33133091
Lancet. 2020 Dec 5;396(10265):1817-1828
pubmed: 33278935
Breast. 2015 Jun;24(3):290-3
pubmed: 25702955
Semin Cancer Biol. 2018 Oct;52(Pt 2):16-25
pubmed: 29024776
Breast Cancer Res Treat. 2015 Jan;149(1):255-61
pubmed: 25504083
Anticancer Agents Med Chem. 2022;22(4):787-800
pubmed: 34229592
N Engl J Med. 2022 Feb 10;386(6):556-567
pubmed: 35139274
Gut. 2017 May;66(5):794-801
pubmed: 26801886
Breast Cancer Res Treat. 2013 May;139(1):183-92
pubmed: 23576078
Adv Exp Med Biol. 2020;1252:87-93
pubmed: 32816266
Breast Cancer Res Treat. 2017 Jun;163(3):417-421
pubmed: 28365832
Ann Surg Oncol. 2018 Apr;25(4):937-946
pubmed: 29330719
JNCI Cancer Spectr. 2018 Dec 13;2(4):pky056
pubmed: 31360876
NPJ Breast Cancer. 2018 Aug 6;4:23
pubmed: 30109263
J Clin Oncol. 2013 Jul 10;31(20):2532-9
pubmed: 23610117
Breast Cancer Res Treat. 2021 Jul;188(2):489-500
pubmed: 34132938
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
J Thorac Dis. 2013 Jun;5 Suppl 1:S62-7
pubmed: 23819029
Ann Oncol. 2017 Aug 1;28(8):1700-1712
pubmed: 28838210
Breast Cancer Res Treat. 2016 Nov;160(2):347-360
pubmed: 27683280
J Vis Exp. 2017 Dec 5;(130):
pubmed: 29286417
Crit Rev Oncol Hematol. 2022 Apr;172:103643
pubmed: 35217131
Histopathology. 2020 Aug;77(2):181-185
pubmed: 32056259
Cell Rep. 2020 Jun 23;31(12):107784
pubmed: 32579916
J Thorac Oncol. 2017 May;12(5):850-859
pubmed: 28257959
Horm Behav. 2012 Aug;62(3):263-71
pubmed: 22406114
Breast. 2017 Oct;35:69-77
pubmed: 28651116
Front Mol Biosci. 2022 Mar 15;9:834651
pubmed: 35372498
Ecancermedicalscience. 2020 Dec 03;14:1150
pubmed: 33574895
Histopathology. 2017 May;70(6):906-917
pubmed: 28072477
Arch Pathol Lab Med. 2021 Jul 1;145(7):887-890
pubmed: 33112946
Front Oncol. 2021 Aug 24;11:723693
pubmed: 34504801
Breast. 2016 Dec;30:215-216
pubmed: 27371969
Front Immunol. 2019 Apr 18;10:846
pubmed: 31057559
Arch Pathol Lab Med. 2020 May;144(5):545-563
pubmed: 31928354
J Mammary Gland Biol Neoplasia. 2009 Jun;14(2):87-98
pubmed: 19381788
J Clin Oncol. 2008 Jul 1;26(19):3153-8
pubmed: 18490649

Auteurs

Elham Sajjadi (E)

Department of Oncology and Hemato-Oncology, University of Milan, Via Festa del Perdono 7, 20122 Milan, Italy.
Division of Pathology, IEO, European Institute of Oncology IRCCS, Via Giuseppe Ripamonti 435, 20141 Milan, Italy.

Konstantinos Venetis (K)

Department of Oncology and Hemato-Oncology, University of Milan, Via Festa del Perdono 7, 20122 Milan, Italy.
Division of Pathology, IEO, European Institute of Oncology IRCCS, Via Giuseppe Ripamonti 435, 20141 Milan, Italy.

Marianna Noale (M)

National Research Council (CNR), Neuroscience Institute Aging Branch, Via Giustiniani 2, 35128 Padua, Italy.

Hatem A Azim (HA)

Breast Cancer Center, Hospital Zambrano Hellion, Tecnologico de Monterrey, San Pedro Garza Garcia 66278, NL, Mexico.

Concetta Blundo (C)

Breast Surgery Unit, Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, 20122 Milan, Italy.

Giuseppina Bonizzi (G)

Division of Pathology, IEO, European Institute of Oncology IRCCS, Via Giuseppe Ripamonti 435, 20141 Milan, Italy.

Eugenia Di Loreto (E)

Gynecology Unit, Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, 20122 Milan, Italy.

Giovanna Scarfone (G)

Gynecology Unit, Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, 20122 Milan, Italy.

Stefano Ferrero (S)

Division of Pathology, Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, 20122 Milan, Italy.
Department of Biomedical, Surgical, and Dental Sciences, University of Milan, Via Festa del Perdono 7, 20122 Milan, Italy.

Stefania Maggi (S)

National Research Council (CNR), Neuroscience Institute Aging Branch, Via Giustiniani 2, 35128 Padua, Italy.

Massimo Barberis (M)

Division of Pathology, IEO, European Institute of Oncology IRCCS, Via Giuseppe Ripamonti 435, 20141 Milan, Italy.

Paolo Veronesi (P)

Department of Oncology and Hemato-Oncology, University of Milan, Via Festa del Perdono 7, 20122 Milan, Italy.
Division of Breast Surgery, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.

Viviana E Galimberti (VE)

Division of Breast Surgery, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.

Giuseppe Viale (G)

Department of Oncology and Hemato-Oncology, University of Milan, Via Festa del Perdono 7, 20122 Milan, Italy.
Division of Pathology, IEO, European Institute of Oncology IRCCS, Via Giuseppe Ripamonti 435, 20141 Milan, Italy.

Nicola Fusco (N)

Department of Oncology and Hemato-Oncology, University of Milan, Via Festa del Perdono 7, 20122 Milan, Italy.
Division of Pathology, IEO, European Institute of Oncology IRCCS, Via Giuseppe Ripamonti 435, 20141 Milan, Italy.

Fedro A Peccatori (FA)

Fertility and Procreation Unit, Division of Gynecologic Oncology, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy.

Elena Guerini-Rocco (E)

Department of Oncology and Hemato-Oncology, University of Milan, Via Festa del Perdono 7, 20122 Milan, Italy.
Division of Pathology, IEO, European Institute of Oncology IRCCS, Via Giuseppe Ripamonti 435, 20141 Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH